NEW HAVEN, Conn., Aug. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a review of recent accomplishments and anticipated upcoming developments. Vlad Coric, M.D., Chairman and Chief Executive Officer of ...

Core Viewpoint - The complaint against Biohaven alleges violations of federal securities laws due to misleading statements regarding the regulatory prospects of its drug troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder, which could significantly impact the company's business and financial condition [2]. Group 1 - Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share following the announcement of an extended PDUFA date for the troriluzole NDA, indicating market reaction to regulatory uncertainties [3]. - The FDA extended the PDUFA date for the troriluzole NDA by three months to allow for a full review of recent submissions, and an advisory committee meeting is planned but not yet scheduled [3]. Group 2 - The lead plaintiff in the class action is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [4]. - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. Group 3 - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Biohaven's conduct to come forward, including whistleblowers and former employees [5].

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder, which were overstated [2]. - The complaint suggests that the revelation of these misstatements is likely to have a significant negative impact on Biohaven's business and financial condition [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's product candidates and their regulatory prospects [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 24, 2023, to May 14, 2025 [3]. - Allegations include that Biohaven overstated the regulatory prospects of its product candidate, troriluzole, for treating SCA, and the efficacy of BHV-7000 for bipolar disorder [3]. - The complaint claims that these misrepresentations are likely to have a significant negative impact on Biohaven's business and financial condition once revealed [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 12, 2025, to potentially be appointed as lead plaintiff [4]. - Registration will provide shareholders with portfolio monitoring software for status updates throughout the case [4]. Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Points - A class action lawsuit has been filed against Biohaven Ltd. in the U.S. District Court for the District of Connecticut on behalf of investors who acquired Biohaven securities during the period from March 24, 2023, to May 14, 2025 [1][3] - Investors have until September 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1][3] Allegations - The lawsuit claims that Biohaven made false or misleading statements regarding the likelihood of regulatory approval for its drug troriluzole to treat SCA, as well as the strength of the supporting data [4] - Additionally, it is alleged that Biohaven overstated the effectiveness and clinical potential of BHV-7000 as a treatment for bipolar disorder [4]

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and overstated its efficacy for treating spinocerebellar ataxia (SCA) [2]. - It is alleged that the clinical prospects of another product, BHV-7000, for treating bipolar disorder were also overstated, which could significantly harm Biohaven's business and financial condition once revealed [2]. - The defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Biohaven Ltd. is facing a class action lawsuit due to alleged false and misleading statements regarding its drug candidates, leading to significant stock price declines during the class period from March 24, 2023, to May 14, 2025 [1][4]. Company Overview - Biohaven is a biopharmaceutical company focused on therapies in immunology, neuroscience, and oncology, with key product candidates including troriluzole for spinocerebellar ataxia and BHV-7000 for bipolar disorder [3]. Allegations and Impact - The class action lawsuit claims that Biohaven overstated the regulatory prospects of troriluzole and the efficacy of BHV-7000, which misled investors and resulted in substantial financial losses [4][6]. - Specific disclosures that negatively impacted Biohaven's stock price include: - On July 27, 2023, the FDA refused to review the NDA for troriluzole, causing a nearly 23% drop in stock price [6]. - On March 3, 2025, disappointing clinical trial results for BHV-7000 led to a nearly 14% decline [6]. - On April 25, 2025, the withdrawal of the Marketing Authorization Application for troriluzole in Europe resulted in over a 15% drop [6]. - On May 14, 2025, the FDA extended the PDUFA date for the troriluzole NDA, causing a more than 19% decline in stock price [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements about the company's product candidates and their regulatory prospects [1][2]. Group 1: Allegations - The complaint alleges that during the class period from March 24, 2023, to May 14, 2025, Biohaven's statements regarding the regulatory prospects of its product candidate, troriluzole, were overstated [1]. - It is claimed that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were also overstated [1]. - The revelations of these issues are likely to have a significant negative impact on Biohaven's business and financial condition [1]. Group 2: Class Action Details - Shareholders who purchased shares of BHVN during the specified class period are encouraged to register for the class action, with a deadline of September 12, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Biohaven Ltd. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's drug candidates and their regulatory prospects [3][5]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $50,000 in Biohaven between March 24, 2023, and May 14, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Biohaven, with a deadline of September 12, 2025, for investors to seek the role of lead plaintiff [3]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against Biohaven - The complaint alleges that Biohaven and its executives made false and misleading statements regarding the regulatory prospects of the drug troriluzole for treating spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder [5]. - It is claimed that the overstated regulatory prospects and clinical data, once revealed, would significantly negatively impact Biohaven's business and financial condition [5]. - Following a press release on May 14, 2025, regarding an extension of the PDUFA date for troriluzole, Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share [6]. Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The firm encourages anyone with information regarding Biohaven's conduct, including whistleblowers and former employees, to contact them [8].

NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission ...